Whereas studies were presenting a sensitivity level for CEA ranging from 65% to 74% in CRC patients, CA19-9 only had sensitivity ranging from 26% to 48% [14,22,23]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.